Pregnancy: There is no data on the clinical experience for the use of Dermatophagoides pteronyssinus extract and Dermatophagoides farinae extract (Acarizax) in pregnant women. Animal studies do not indicate increased risk to the fetus. Treatment with Dermatophagoides pteronyssinus extract and Dermatophagoides farinae extract (Acarizax) should not be initiated during pregnancy. If pregnancy occurs during treatment, the treatment may continue after evaluation of the general condition (including lung function) of the patient and reactions to previous administration of Dermatophagoides pteronyssinus extract and Dermatophagoides farinae extract (Acarizax). In patients with pre-existing asthma close supervision during pregnancy is recommended.
Lactation: No clinical data are available for the use of Dermatophagoides pteronyssinus extract and Dermatophagoides farinae extract (Acarizax) during lactation. No effects on the breastfed infants are anticipated.
Fertility: There is no clinical data with respect to fertility for the use of Dermatophagoides pteronyssinus extract and Dermatophagoides farinae extract (Acarizax). In a repeat dose toxicity study in mice no effects were observed in the reproductive organs of both genders.